GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2018 | 06-2018 | 03-2018 | 12-2017 | 09-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,232 | 1,096 | 2,870 | 576 | 2,732 |
| TOTAL | $1,247 | $1,096 | $2,870 | $576 | $2,732 |
| Non-Current Assets | |||||
| PPE Net | 5 | 6 | 7 | 6 | 2 |
| Intangibles | 25,263 | 253,777 | 253,777 | 253,777 | 253,777 |
| Other Non-Current Assets | 21 | 135 | 679 | 9 | 9 |
| TOTAL | $25,289 | $253,918 | $254,463 | $253,792 | $253,788 |
| Total Assets | $26,536 | $255,014 | $257,333 | $254,368 | $256,520 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 10,597 | 6,856 | 2,932 | N/A | 0 |
| Accounts payable and accrued liabilities | 2,251 | 1,887 | 1,830 | 2,546 | 2,714 |
| Accrued Expenses | 344 | 178 | 283 | 102 | 57 |
| TOTAL | $13,223 | $8,952 | $5,076 | $2,679 | $2,802 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $13,223 | $8,952 | $5,076 | $2,679 | $2,802 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 98 | 98 | 98 | 98 | 97 |
| Common Shares | 50 | 50 | 50 | 50 | 50 |
| Retained earnings | -524,453 | -288,670 | -279,589 | -269,499 | -261,870 |
| Other shareholders' equity | -167 | -167 | -167 | -167 | -168 |
| TOTAL | $13,313 | $246,062 | $252,257 | $251,689 | $253,718 |
| Total Liabilities And Equity | $26,536 | $255,014 | $257,333 | $254,368 | $256,520 |